Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A3 | P38919 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14964461 | 0.83 | EIF4A3 (0.35) | EIF4A3PDE2AACE2FEN1 | |
| SCHEMBL15417382 | 0.83 | EIF4A3 (0.35) | EIF4A3PDE2AACE2FEN1 | |
| SCHEMBL20226998 | 0.82 | EIF4A3 (0.34) | EIF4A3ACE2P2RX7 | |
| SCHEMBL17128822 | 0.81 | ACE2 (0.42) | EIF4A3ACE2P2RX7GABRA1GABRG2 | |
| SCHEMBL27342163 | 0.81 | CTSS (0.40) | EIF4A3FEN1GABRA1 | |
| SCHEMBL14132473 | 0.81 | GABRA1 (0.42) | EIF4A3GABRA1GABRG2GABRB3ANPEP | |
| SCHEMBL12173269 | 0.81 | EIF4A3 (0.41) | EIF4A3PDE2AGABRA1GABRG2GABRB3 | |
| SCHEMBL19196278 | 0.81 | GABRA1 (0.39) | PDE2AFEN1P2RX7GABRA1 | |
| SCHEMBL7762549 | 0.77 | GABRA1 (0.39) | PDE2AFEN1GABRA1 | |
| SCHEMBL22483857 | 0.76 | EIF4A3 (0.30) | EIF4A3ANPEPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2022-07-07 | — | — | US | disclosed |
| US-11214560-B2 | Modulators of P97 AAA ATPase activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3523313-B1 | DIBENZO[D,B]SILOLE-BASED REACTIVE MESOGENS | LOMOX LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| US-20200216410-A1 | MODULATORS OF P97 AAA ATPASE ACTIVITY | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200155536-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2020-05-21 | — | — | US | disclosed |
| US-10464905-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190000806-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | EIF4A3 4673/4885PDE2A 532/4885ACE2 725/4885 |
| US-20200155536-A1 | P97 INHIBITORS FOR TREATING CANCER AND NEURODEGENERATIVE DISORDERS | PML, TARDBP, PRNP | EIF4A3 1324/4885PDE2A 3769/4885ACE2 3208/4885 |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | EIF4A3 4673/4885PDE2A 532/4885ACE2 725/4885 |
| US-20200216410-A1 | MODULATORS OF P97 AAA ATPASE ACTIVITY | PSMG3, AHSA1, CDC37 | EIF4A3 918/4885PDE2A 3740/4885ACE2 1129/4885 |
| US-11214560-B2 | Modulators of P97 AAA ATPase activity | PSMG3, AHSA1, CDC37 | EIF4A3 918/4885PDE2A 3740/4885ACE2 1129/4885 |
| US-10464905-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | EIF4A3 1427/4885PDE2A 2053/4885ACE2 3159/4885 |
| US-20190000806-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | EIF4A3 1427/4885PDE2A 2053/4885ACE2 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.